Research programme: bromodomain inhibitors - Roche

Drug Profile

Research programme: bromodomain inhibitors - Roche

Alternative Names: JQ-1; RO6870810

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Roche
  • Class Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Mar 2017 Hoffmann-La Roche plans a phase I trial of RO 6870810 for Multiple myeloma (Monotherapy, Combination therapy, Late-stage disease, Relapsed/Refractory) in USA (NCT03068351)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Cancer presented at 58th Annual Meeting and Exposition of the American Society of Hematology
  • 28 Nov 2013 Preclinical development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top